RS63601B1 - Vektor ekspresije car i t ćelije koje eksprimiraju car - Google Patents

Vektor ekspresije car i t ćelije koje eksprimiraju car

Info

Publication number
RS63601B1
RS63601B1 RS20220895A RSP20220895A RS63601B1 RS 63601 B1 RS63601 B1 RS 63601B1 RS 20220895 A RS20220895 A RS 20220895A RS P20220895 A RSP20220895 A RS P20220895A RS 63601 B1 RS63601 B1 RS 63601B1
Authority
RS
Serbia
Prior art keywords
car
expressing
cells
expression vector
car expression
Prior art date
Application number
RS20220895A
Other languages
English (en)
Serbian (sr)
Inventor
Koji Tamada
Yukimi Sakoda
Keishi Adachi
Original Assignee
Univ Yamaguchi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yamaguchi filed Critical Univ Yamaguchi
Publication of RS63601B1 publication Critical patent/RS63601B1/sr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/26—Lymph; Lymph nodes; Thymus; Spleen; Splenocytes; Thymocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464424—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464436—Cytokines
    • A61K39/46444—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464436—Cytokines
    • A61K39/464442—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5418—IL-7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/21—Chemokines, e.g. MIP-1, MIP-2, RANTES, MCP, PF-4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
RS20220895A 2014-10-09 2015-10-06 Vektor ekspresije car i t ćelije koje eksprimiraju car RS63601B1 (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014208200 2014-10-09
EP19196196.0A EP3597742B1 (en) 2014-10-09 2015-10-06 Car expression vector and car-expressing t cells

Publications (1)

Publication Number Publication Date
RS63601B1 true RS63601B1 (sr) 2022-10-31

Family

ID=55652864

Family Applications (2)

Application Number Title Priority Date Filing Date
RSP20191315 RS59441B1 (sr) 2014-10-09 2015-10-06 Car ekspresioni vektor i t ćelije koje eksprimiraju car
RS20220895A RS63601B1 (sr) 2014-10-09 2015-10-06 Vektor ekspresije car i t ćelije koje eksprimiraju car

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RSP20191315 RS59441B1 (sr) 2014-10-09 2015-10-06 Car ekspresioni vektor i t ćelije koje eksprimiraju car

Country Status (28)

Country Link
US (3) US10316102B2 (ja)
EP (2) EP3205720B1 (ja)
JP (5) JP6161098B2 (ja)
KR (1) KR101890638B1 (ja)
CN (1) CN107109421B (ja)
AU (1) AU2015329444B2 (ja)
BR (1) BR112017006710B1 (ja)
CA (1) CA2962375C (ja)
CY (1) CY1122324T1 (ja)
DK (2) DK3597742T3 (ja)
ES (2) ES2751945T3 (ja)
HR (2) HRP20221211T1 (ja)
HU (2) HUE060047T2 (ja)
IL (1) IL251504B (ja)
LT (2) LT3205720T (ja)
MX (1) MX358472B (ja)
MY (1) MY167722A (ja)
NZ (1) NZ730382A (ja)
PH (1) PH12017500596A1 (ja)
PL (2) PL3597742T3 (ja)
PT (2) PT3597742T (ja)
RS (2) RS59441B1 (ja)
RU (1) RU2670147C1 (ja)
SG (1) SG11201702391RA (ja)
SI (2) SI3597742T1 (ja)
TW (1) TWI688651B (ja)
WO (1) WO2016056228A1 (ja)
ZA (1) ZA201701968B (ja)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3597742T3 (pl) * 2014-10-09 2022-11-14 Yamaguchi University Wektor ekspresyjny CAR oraz komórki T wykazujące ekspresję CAR
GB201509413D0 (en) * 2015-06-01 2015-07-15 Ucl Business Plc Fusion protein
EP3416686A1 (en) 2016-02-16 2018-12-26 Dana Farber Cancer Institute, Inc. Immunotherapy compositions and methods
WO2017159736A1 (ja) * 2016-03-17 2017-09-21 国立大学法人山口大学 免疫機能制御因子を発現する免疫担当細胞及び発現ベクター
US11447562B2 (en) * 2017-01-01 2022-09-20 Chi-Yu Gregory Lee RP215 chimeric antigen receptor construct and methods of making and using same
TWI831365B (zh) 2017-01-10 2024-02-01 國立大學法人山口大學 抗ｇｐｃ３抗體
CN116874608A (zh) * 2017-03-27 2023-10-13 诺伊尓免疫生物科技株式会社 嵌合抗原受体
CN108484777B (zh) * 2017-03-31 2022-07-12 李吉祐 人源化rp215单克隆抗体的嵌合抗原受体构建体及核酸分子与应用
CN111163758A (zh) 2017-10-10 2020-05-15 国立大学法人山口大学 具有记忆功能的t细胞或b细胞的增强剂、恶性肿瘤复发抑制剂、以及对t细胞或b细胞诱导记忆功能的诱导剂
IL275453B1 (en) * 2017-12-24 2024-02-01 Noile Immune Biotech Inc An immunocompetent cell expressing a cell surface compound that specifically recognizes human mesothelin, IL-7, and CCL19
BR112020013201A2 (pt) * 2017-12-27 2020-12-01 Takeda Pharmaceutical Company Limited nanopartícula lipídica, medicamento, métodos para expressar um receptor, para prevenir ou tratar câncer e para produzir um medicamento, uso da nanopartícula lipídica e do imunócito ex vivo, composição, imunócito ex vivo, e, célula ex vivo
CN108659133A (zh) * 2018-04-26 2018-10-16 上海怡豪生物科技有限公司 肺癌的双靶点car-t治疗载体及其构建方法和应用
CN108641000A (zh) * 2018-04-26 2018-10-12 上海怡豪生物科技有限公司 肝癌的双靶点car-t治疗载体及其构建方法和应用
CN108641001A (zh) * 2018-04-26 2018-10-12 上海怡豪生物科技有限公司 结肠癌的双靶点car-t治疗载体及其构建方法和应用
KR20210018838A (ko) * 2018-05-15 2021-02-18 카르스젠 테라퓨틱스 컴퍼니, 리미티드 유전자 조작된 세포 및 응용
KR20190141511A (ko) * 2018-06-14 2019-12-24 주식회사 녹십자랩셀 신규 펩티드, 이를 포함하는 키메라 항원 수용체 및 이를 발현하는 면역 세포
CN108866004A (zh) * 2018-06-26 2018-11-23 奥妙生物技术（广州）有限公司 Shp-1敲除的t细胞及其构建方法
JPWO2020017479A1 (ja) * 2018-07-17 2021-08-02 ノイルイミューン・バイオテック株式会社 抗ｇｐｃ３一本鎖抗体を含むｃａｒ
CN109055430A (zh) * 2018-08-14 2018-12-21 杭州荣泽生物科技有限公司 一种共表达il18和ccl19蛋白及靶向muc1基因car-t细胞的制备方法
TW202016295A (zh) * 2018-08-31 2020-05-01 日商諾伊爾免疫生物科技股份有限公司 Car表現t細胞及car表現載體
WO2020057641A1 (zh) * 2018-09-20 2020-03-26 科济生物医药（上海）有限公司 表达有趋化因子的细胞及用途
EP3864142A4 (en) * 2018-10-12 2023-07-19 iCell Gene Therapeutics LLC CHIMERIC ANTIGEN RECEPTOR (CARS) COMPOSITIONS AND METHODS OF USE THEREOF
CN109504660B (zh) * 2018-11-02 2021-08-06 温州启星生物技术有限公司 一种第四代car-t细胞及其构建方法和应用
US20220033848A1 (en) * 2018-11-19 2022-02-03 Board Of Regents, The University Of Texas System A modular, polycistronic vector for car and tcr transduction
EP3934666A1 (en) * 2019-03-08 2022-01-12 Autolus Limited Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
CN112080526A (zh) * 2019-06-14 2020-12-15 南京艾德免疫治疗研究院有限公司 表达il-7和car的表达载体及免疫细胞
CN112080525A (zh) * 2019-06-14 2020-12-15 南京艾德免疫治疗研究院有限公司 一种改良型嵌合抗原受体t细胞的制备
JP2021016371A (ja) * 2019-07-23 2021-02-15 株式会社東芝 Ｃａｒ−ｔ細胞の製造方法、核酸導入キャリア及びキット
WO2021085497A1 (ja) 2019-10-28 2021-05-06 ノイルイミューン・バイオテック株式会社 がんを治療するための医薬、組み合わせ医薬、医薬組成物、免疫応答性細胞、核酸送達媒体、及び製品
CN110922490B (zh) * 2019-12-05 2023-03-03 浙江启新生物技术有限公司 分泌白介素7和趋化因子21的car表达载体及应用
WO2021162521A1 (ko) * 2020-02-14 2021-08-19 (주)이뮤노텍바이오팜코리아 외부에서 도입된 세포 신호 조절 인자를 과발현하는 면역 세포 및 이들의 용도
CN113528483A (zh) * 2020-04-22 2021-10-22 复星凯特生物科技有限公司 Shp2特异性失活突变蛋白及其在car-t治疗中应用
GB202006820D0 (en) * 2020-05-07 2020-06-24 Autolus Ltd Cell
US20230257705A1 (en) 2020-06-17 2023-08-17 Kyoto University Chimeric antigen receptor-expressing immunocompetent cells
KR102297396B1 (ko) 2020-07-29 2021-09-06 (주)티카로스 면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포
CN116782937A (zh) 2020-12-10 2023-09-19 优特力克斯有限公司 抗pd-1抗体及其用途
WO2022135357A1 (en) * 2020-12-22 2022-06-30 Sunshine Lake Pharma Co., Ltd. A hIL7/hCCL19 DOUBLE GENE RECOMBINANT ONCOLYTIC VIRUS AND ITS PREPARATION METHOD AND USE
CN114716548A (zh) 2021-01-05 2022-07-08 (株)爱恩德生物 抗-fgfr3抗体及其用途
CN112961248B (zh) * 2021-02-22 2022-03-18 广州百暨基因科技有限公司 共表达IL-7和CCR2b的嵌合抗原受体融合蛋白及其应用
WO2022245098A1 (ko) 2021-05-18 2022-11-24 주식회사 바이오솔루션 세포외소포체 분비능이 증진된 면역세포 및 이를 활용한 면역 항암요법
KR20240040068A (ko) 2021-07-29 2024-03-27 다케다 야쿠힌 고교 가부시키가이샤 메조텔린을 특이적으로 표적화하는 조작된 면역 세포 및 이의 용도
CN113913385A (zh) * 2021-09-01 2022-01-11 苏州璞惠卓越生物科技有限公司 一种抑制蛋白阻断型嵌合抗原受体修饰的免疫细胞及其用途
CN113921082B (zh) * 2021-10-27 2023-04-07 云舟生物科技(广州)股份有限公司 基因搜索权重调整方法、计算机存储介质及电子设备
WO2023081455A2 (en) * 2021-11-08 2023-05-11 Memorial Sloan-Kettering Cancer Center Immune cells expressing glucose transporter 5 (gluts) and compositions and methods including the same
WO2023223292A1 (en) * 2022-05-20 2023-11-23 Takeda Pharmaceutical Company Limited Methods of producing engineered immune cells
CN115505601A (zh) * 2022-10-17 2022-12-23 深圳市先康达生命科学有限公司 一种两级SynNotch逻辑调控结构及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5857318A (ja) * 1981-10-01 1983-04-05 Nippon Koutai Kenkyusho:Kk 癌細胞障害性リンパ球の製造法
WO2002077029A2 (en) 2000-11-07 2002-10-03 City Of Hope Cd19-specific redirected immune cells
KR20050118057A (ko) * 2004-04-24 2005-12-15 김상희 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품
TWI436775B (zh) * 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌
KR101361416B1 (ko) * 2008-10-08 2014-02-21 인트렉손 코포레이션 다수의 면역조절자를 발현하는 조작된 세포 및 그 용도
CN106220739A (zh) 2010-12-09 2016-12-14 宾夕法尼亚大学董事会 嵌合抗原受体‑修饰的t细胞治疗癌症的用途
WO2012082841A2 (en) 2010-12-14 2012-06-21 University Of Maryland, Baltimore Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
US9266960B2 (en) 2011-04-08 2016-02-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of same for the treatment of cancer
US20130071414A1 (en) * 2011-04-27 2013-03-21 Gianpietro Dotti Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
WO2013040371A2 (en) * 2011-09-16 2013-03-21 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
JP6053688B2 (ja) 2011-10-07 2016-12-27 国立大学法人三重大学 キメラ抗原受容体
AU2013221672B2 (en) * 2012-02-13 2017-11-09 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
AU2013222284A1 (en) * 2012-02-22 2014-08-07 The Trustees Of The University Of Pennsylvania Use of the CD2 signaling domain in second-generation chimeric antigen receptors
CN102625373A (zh) 2012-02-22 2012-08-01 中兴通讯股份有限公司 一种智能载波管理方法及装置
PL3597742T3 (pl) * 2014-10-09 2022-11-14 Yamaguchi University Wektor ekspresyjny CAR oraz komórki T wykazujące ekspresję CAR

Also Published As

Publication number Publication date
NZ730382A (en) 2019-01-25
KR20170067773A (ko) 2017-06-16
IL251504B (en) 2020-03-31
PH12017500596B1 (en) 2017-08-30
AU2015329444B2 (en) 2017-11-23
MX358472B (es) 2018-08-21
KR101890638B1 (ko) 2018-08-22
EP3205720A1 (en) 2017-08-16
CA2962375A1 (en) 2016-04-14
DK3597742T3 (da) 2022-10-03
CN107109421A (zh) 2017-08-29
PH12017500596A1 (en) 2017-08-30
EP3205720B1 (en) 2019-09-11
ZA201701968B (en) 2019-06-26
EP3597742B1 (en) 2022-07-13
ES2927366T3 (es) 2022-11-04
WO2016056228A1 (ja) 2016-04-14
US10906984B2 (en) 2021-02-02
TWI688651B (zh) 2020-03-21
MY167722A (en) 2018-09-21
SG11201702391RA (en) 2017-04-27
LT3205720T (lt) 2019-12-10
IL251504A0 (en) 2017-05-29
MX2017004393A (es) 2017-06-22
JP7300763B2 (ja) 2023-06-30
DK3205720T3 (da) 2019-10-07
PT3205720T (pt) 2019-10-28
US20210253726A1 (en) 2021-08-19
JP6161098B2 (ja) 2017-07-12
CA2962375C (en) 2020-07-14
BR112017006710B1 (pt) 2020-01-21
CY1122324T1 (el) 2021-01-27
ES2751945T3 (es) 2020-04-02
RS59441B1 (sr) 2019-11-29
JP2023116674A (ja) 2023-08-22
JP7008350B2 (ja) 2022-02-10
HUE046710T2 (hu) 2020-03-30
PT3597742T (pt) 2022-08-30
HRP20191839T1 (hr) 2020-01-24
AU2015329444A1 (en) 2017-04-13
CN107109421B (zh) 2018-09-25
PL3597742T3 (pl) 2022-11-14
JP2017153487A (ja) 2017-09-07
BR112017006710A2 (pt) 2017-12-12
JP2022048153A (ja) 2022-03-25
US20190322755A1 (en) 2019-10-24
JP2020108398A (ja) 2020-07-16
US20170291953A1 (en) 2017-10-12
HUE060047T2 (hu) 2023-01-28
SI3597742T1 (sl) 2022-11-30
EP3597742A1 (en) 2020-01-22
US10316102B2 (en) 2019-06-11
RU2670147C1 (ru) 2018-10-18
SI3205720T1 (sl) 2020-01-31
LT3597742T (lt) 2022-09-12
PL3205720T3 (pl) 2020-02-28
EP3205720A4 (en) 2018-07-04
HRP20221211T1 (hr) 2022-12-09
TW201619377A (zh) 2016-06-01
JP6683990B2 (ja) 2020-04-22
JPWO2016056228A1 (ja) 2017-06-01

Similar Documents

Publication Publication Date Title
IL251504B (en) car expression vector and t cells expressing car
IL274903A (en) cell
IL252216B (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
HK1231471A1 (zh) -雜芳氧基-和 芳氧基-喹啉- -甲酰胺及其用途
GB201403684D0 (en) Vector
GB201616238D0 (en) Modified T cells
PL3091590T3 (pl) Ogniwo akumulatorowe zawierające element zapobiegający fałdowaniu
PL2952406T3 (pl) Wózek i przyczepa
GB201408091D0 (en) Methods and uses
PL3149792T3 (pl) Ogniwo litowo-siarkowe
GB201604427D0 (en) Modified cell
IL236273A0 (en) Cells and battery organizers
GB201416086D0 (en) Methods and uses
GB201416073D0 (en) Methods and uses
GB201410934D0 (en) T cell